VivoSeq
Other

Hypospadias

27

Pipeline Programs

7

Active Trials

11

Companies Involved

Hypospadias is an emerging landscape with 27 programs across 11 companies. The most active players are TLC Biopharmaceuticals, Inc., Merck & Co., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 12 therapies are approved with 6 more in late-stage development.

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

11/100

Mech. Concentration

19/100

Completion Rate

83/100

Attrition Rate

7/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

27

clinical trials

Completed10 · 37%
Unknown status8 · 30%
Recruiting4 · 15%
Not yet recruiting2 · 7%
Active, not recruiting1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Trial Activity

27 trials

Prophylactic Antibiotics or Placebo After Hypospadias Repair
Active, not recruiting··N/A·NCT02096159·93 enrolled
Dexmedetomidine Infusion in Hypospadias Surgery
Completed·UUniversity of Jordan·Phase 3·NCT00926705·48 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)